GT Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Breen and Manu Ohri, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution for him, and in his name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Position | Date |
|---|---|---|
| /s/ Michael Breen | Executive Chairman of the Board and | March 26, 2024 |
| Michael Breen | Interim Chief Executive Officer (Principal Executive Officer) | |
| /s/ Manu Ohri | Chief Financial Officer | March 26, 2024 |
| Manu Ohri | (Principal Financial and Accounting Officer) | |
| /s/ Bruce Wendel | Vice Chairman of the Board | March 26, 2024 |
| Bruce Wendel | ||
| /s/ Rajesh Shrotriya | Director | March 26, 2024 |
| Rajesh Shrotriya, M.D. | ||
| /s/ Charles Casamento | Director | March 26, 2024 |
| Charles Casamento | ||
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO FINANCIAL STATEMENTS
| Financial Statements of GT Biopharma, Inc. | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB Firm ID: 572) | F-2 |
| Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022 | F-4 |
| Consolidated Statements of Operations for the year ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Stockholders’ Equity for the year ended December 31, 2023 and 2022 | F-6 |
| Consolidated Statements of Cash Flows for the year ended December 31, 2023 and 2022 | F-7 |
| Notes to the Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.